Tokyo, Jan 31, 2012 (JCN) - In line with its commitment to support the World Health Organization's lymphatic filariasis elimination program, Eisai Co., Ltd, as one of the 13 major research and development-based pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank and governments from neglected tropical disease (NTD)-endemic countries, gave its support on January 30 (local London time) to the London Declaration, a coordinated effort to eliminate 10 NTDs by the end of this decade.
Eisai is committed to taking proactive steps to address issues related to access to medicines, including NTDs, in accordance with established policy as it expands its business in both emerging and developing nations in this era of great globalization. The company considers its contributions to the economic development and expansion of the middle-income class through the enhancement of health and welfare in these countries as a form of long-term investment for future growth.
Eisai is the only Japanese company to join this coordinated program. In support of the London Declaration and the WHO's program to eliminate lymphatic filariasis, Eisai has signed an agreement with the WHO to extend its support until 2020, during which Eisai will supply free of charge 2.2 billion tablets of the medicine DEC (diethylcarbamazine) until 2020, in line with the WHO elimination goals.
Eisai will start manufacturing DEC in accordance with the high quality standards of WHO at its plant in Vizag, India, and provide it to people in need as a price "zero" Eisai product, while working on the collection and provision of relevant safety information to ensure the appropriate use of the medicine. Eisai will begin supplying DEC from 2013, and plans to deliver this medicine to some 250 million people in the developing world by 2020.
Eisai has also committed to provide 120 million DEC tablets to the WHO free of charge in collaboration with Sanofi and the Bill & Melinda Gates Foundation to ensure a stable of supply of DEC until 2013 when the Eisai-produced DEC becomes available. This is the first partnership in which two pharmaceutical companies, with the Gates Foundation, have come together to supply a single drug for an NTD.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting
(Apr 10, 2013)
|
|
|
Eisai Co-establishes the Global Health Innovative Technology Fund
(Apr 8, 2013)
|
|
|
Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct Sales Launch in Russia
(Apr 5, 2013)
|
|
|
Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc(R) intramuscular Injection 2500 Units in Japan
(Mar 26, 2013)
|
|
|
Eisai Recieves Manufacturing and Marketing Authorization for Antiepileptic Agent Inovelon(R) in Japan
(Mar 25, 2013)
|
|
|
Eisai Announces Launch of Chocola BB(R) Sparkling + Fiber, Containing 5 Ingredients that Help Bring Out Beauty from Within
(Feb 26, 2013)
|
|
|
Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer
(Jan 11, 2013)
|
|
|
Noblepharma and Eisai Announce Japan Lunch of Antineoplastic Agent Gliadel(R) 7.7 mg Implant
(Jan 8, 2013)
|
|
|
Eisai Signs Agreement with Epizyme and Roche Molecular Systems to Develop Companion Diagnostic
(Jan 8, 2013)
|
|
|
Eisai Signs Global Agreement with Fundacao Oswaldo Cruz to Begin Development of New Medicines and Vaccines for Malaria and Neglected Tropical Diseases
(Oct 25, 2012)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Medical news...
|
|
